$8.82
1.50% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

PepGen Stock price

$8.82
-0.75 7.84% 1M
-5.27 37.40% 6M
+2.02 29.71% YTD
+3.69 71.93% 1Y
-4.07 31.57% 3Y
-4.07 31.57% 5Y
-4.07 31.57% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.13 1.50%
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

Key metrics

Market capitalization $283.20m
Enterprise Value $141.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.82
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-95.81m
Free Cash Flow (TTM) Free Cash Flow $-75.28m
Cash position $161.31m
EPS (TTM) EPS $-3.30
P/E forward negative
Short interest 5.49%
Show more

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a PepGen forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a PepGen forecast:

Buy
80%
Hold
20%

Financial data from PepGen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.45 1.45
88% 88%
-
-1.45 -1.45
88% 88%
-
- Selling and Administrative Expenses 18 18
20% 20%
-
- Research and Development Expense 75 75
26% 26%
-
-94 -94
26% 26%
-
- Depreciation and Amortization 1.45 1.45
88% 88%
-
EBIT (Operating Income) EBIT -96 -96
26% 26%
-
Net Profit -89 -89
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Business Wire
8 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher Ashton, PhD, intends to retire from the Board of Directors effective September 30, 2024. Dr. Ashton has served on PepG...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Execut...
Neutral
Accesswire
about one month ago
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO James McArthur
Employees 64
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today